Announcement

Collapse
No announcement yet.

Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published

    This study population was all recurrent GBM patients - not limited to the H3K27M mutant tumors as the current trials are.. They did have one patient, who has the H3K27M mutation, who had multifocal recurrent gbm and had a complete response that has lasted a year and a half so far. They are now testing this drug in clinical trials only with tumors that have this mutation. So although the study did not hit the target endpoint of progression free survival at 6 months, there were a few positives from the study: They think they found the biomarker (H3K27M) that identifies patients where it has a better chance of helping, and they found that the drug gets to the tumor at the correct concentration - it gets through the blood brain barrier. It is also safe.
    Click HERE for the article!
Working...
X